AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights:
Stockhead, IR Department, and Morgans organize HealthInvest 2025 in Sydney, bringing attention to ASX-listed healthcare companies.
Companies including EMVision, Microba, Orthocell, Lumos Diagnostics, and Dimerix will present their latest advancements.
The event will highlight key developments in neuro-diagnostics, microbiome testing, regenerative medicine, and precision diagnostics.
HealthInvest 2025 is set to take place in Sydney, bringing together ASX-listed healthcare companies to present innovations shaping the medical landscape. Organized by Stockhead, IR Department, and Morgans, the event will feature a diverse range of companies contributing to the advancement of healthcare and life sciences.
Neuro-Diagnostics Advancements
EMVision Medical Devices (ASX:EMV) is among the key participants, focusing on neuro-diagnostic tools designed to enhance stroke detection. Its portable brain scanner, EMU, is undergoing pivotal trials in Australia and the US, progressing toward FDA de novo approval. This development aims to transform acute stroke management by providing rapid, non-invasive brain imaging solutions.
Microbiome Testing Expansion
Microba Life Sciences (ASX:MAP) is working on advanced gut microbiome testing solutions with a growing global footprint. A strategic partnership with Sonic Healthcare (ASX:SHL) is accelerating expansion into markets across Australia, Europe, and the US. This approach strengthens diagnostic capabilities in gastrointestinal health and broadens accessibility to precision microbiome analysis.
Regenerative Medicine Developments
Orthocell (ASX:OCC) is advancing regenerative nerve repair solutions with its product, Remplir. The company is awaiting FDA 510(k) approval, following successful regulatory milestones in Australia and Singapore. The technology is designed to enhance nerve regeneration, with implications for improved treatment outcomes in peripheral nerve repair.
Point-of-Care Testing Innovations
Lumos Diagnostics is refining its point-of-care testing portfolio through collaborations with industry leaders. A partnership with Hologic supports the development of a next-generation fetal diagnostic test. Additionally, the FebriDx test is undergoing a CLIA waiver study, aiming to facilitate broader clinical use in differentiating bacterial from non-bacterial infections.
Advancements in Nephrology Treatment
Dimerix is conducting a phase III global trial for DMX-200, addressing focal segmental glomerulosclerosis (FSGS), a rare kidney disorder. The investigational treatment has received multiple international designations, underscoring its relevance in nephrology research. The company continues to advance its clinical programs in collaboration with leading medical institutions.
HealthInvest 2025 serves as a platform to explore advancements in healthcare technology, diagnostics, and treatment development. The event brings together leading ASX-listed companies dedicated to innovation in the medical field, highlighting breakthroughs that are shaping modern healthcare solutions.
